In the last trading session, 7.21 million Intellia Therapeutics Inc (NASDAQ:NTLA) shares changed hands as the company’s beta touched 2.13. With the company’s per share price at $8.09 changed hands at $0.51 or 6.73% during last session, the market valuation stood at $837.99M. NTLA’s last price was a discount, traded about -248.33% off its 52-week high of $28.18. The share price had its 52-week low at $5.90, which suggests the last value was 27.07% up since then.
Analysts gave the Intellia Therapeutics Inc (NTLA) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.62. If we narrow down to specifics, the data shows that 0 out of 13 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended NTLA as a Hold, 13 felt it is a Buy and 0 rated the stock as Underweight. Intellia Therapeutics Inc’s EPS for the current quarter is expected to be -1.01.
Intellia Therapeutics Inc (NASDAQ:NTLA) trade information
Instantly NTLA was in green as seen at the end of in last trading. With action 17.76%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -30.62%, with the 5-day performance at 17.76% in the green. However, in the 30-day time frame, Intellia Therapeutics Inc (NASDAQ:NTLA) is 10.97% up.
The consensus price target for the stock as assigned by Wall Street analysts is 17.5, meaning bulls need an upside of 53.77% from its current market value. According to analyst projections, NTLA’s forecast low is 9 with 26 as the target high. To hit the forecast high, the stock’s price needs a -221.38% plunge from its current level, while the stock would need to soar -11.25% for it to hit the projected low.
Intellia Therapeutics Inc (NTLA) estimates and forecasts
Year-over-year growth is forecast to reach -3.17% down from the last financial year.
Consensus estimates given by 19 financial analysts project the company’s revenue in the current quarter to hit an average of 12.26M. 19 analysts are of the opinion that Intellia Therapeutics Inc’s revenue for the current quarter will be 12.41M. The company’s revenue for the corresponding quarters a year ago was 6.96M and 9.11M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 76.22%. The estimates for the next quarter sales put growth at 36.20%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -20.04%. The 2025 estimates are for Intellia Therapeutics Inc earnings to increase by 20.55%, but the outlook for the next 5-year period is at 31.48% per year.
NTLA Dividends
Intellia Therapeutics Inc is expected to release its next quarterly earnings report in July.
BLACKROCK INC. holds the second largest percentage of outstanding shares, with 9.897% or 9.6 million shares worth $214.79 million as of 2024-06-30.
Among Mutual Funds, the top two as of Apr 30, 2025 were ARK ETF Trust-ARK Innovation ETF and SMALLCAP WORLD FUND INC . With 8.48 shares estimated at $68.63 million under it, the former controlled 8.19% of total outstanding shares. On the other hand, SMALLCAP WORLD FUND INC held about 3.65% of the shares, roughly 3.78 shares worth around $30.58 million.
